Stem Cell Therapy and Innate Lymphoid Cells

Figure 4

ILC2s and mesenchymal stem cells (MSCs) in GvHD and inflammation: MSCs express cyclooxygenase and prostaglandin D2 (PGD2), a ligand for prostaglandin D2 receptor 2, which binds to ILC2 and induces production of type 2 cytokines and inhibits IFN-γ production. MSCs also bind with Treg and induce the expression of IL10 which inhibits ILC2 and progression of GvHD. MSC-derived small extracellular vesicles (sEV) express miR146a-5p which inhibits ILC2 and production of type 2 cytokines.